Profhilo bioremodelling: how it works, what the evidence says, and who it fits

Profhilo is one of the most talked-about injectable treatments in aesthetic medicine, but its positioning is often misunderstood. It is not a dermal filler — it does not add volume or reshape contours. It is not a traditional mesotherapy skin booster either. Profhilo occupies a category called bioremodelling: it uses high concentrations of hyaluronic acid to stimulate the skin's own collagen and elastin production, improving skin quality from within rather than altering facial structure.

This article explains what Profhilo is, how its proprietary NAHYCO technology works, what the published clinical evidence says about efficacy and safety, how it compares to fillers and other injectables, and who is — and is not — a good candidate.

What Profhilo is and how it differs from fillers

Profhilo is manufactured by IBSA Farmaceutici Italia and was first launched in 2015. Each syringe contains 64 mg of hyaluronic acid (HA) — a notably high concentration — split evenly between 32 mg of high-molecular-weight HA (1,100–1,400 kDa) and 32 mg of low-molecular-weight HA (80–100 kDa). The two HA fractions are combined using a proprietary thermal process called NAHYCO (Nano-sized HYbrid COmplex) technology, which creates stable hybrid cooperative complexes (HCCs) without chemical cross-linking agents such as BDDE.

This is a critical distinction from dermal fillers. Fillers use chemically cross-linked HA that forms a gel scaffold to occupy space under the skin. Profhilo's HA is not cross-linked and has very low viscosity. After injection, it spreads through the dermis and subcutaneous tissue rather than staying in one place. Its purpose is not structural — it is biological. The hybrid HA complexes interact with fibroblasts, keratinocytes, and adipose-derived stem cells to trigger new collagen and elastin synthesis.

Because there is no chemical cross-linking, the risk of inflammatory nodules, late-onset swelling, and vascular occlusion — complications associated with cross-linked filler gels — is substantially lower. The tradeoff is that Profhilo produces no immediate volumizing effect. Results build gradually as the skin remodels itself.

How NAHYCO technology works

The NAHYCO manufacturing process mixes high- and low-molecular-weight HA under controlled thermal conditions. The result is a hybrid cooperative complex where the two HA fractions are interlocked at a molecular level without chemical binders. This hybrid structure has several properties that neither HA fraction has alone:

• Resistance to enzymatic degradation. Hyaluronidase breaks down native HA within hours to days. The HCC structure degrades more slowly, giving the product enough residence time in tissue to stimulate a biological response.
• Sustained release. The hybrid complex gradually releases both high- and low-molecular-weight HA, providing ongoing stimulation of fibroblasts and keratinocytes over weeks.
• Adipocyte activation. In vitro studies by Stellavato et al. (2017) published in Cell Physiology and Biochemistry showed that HCCs enhance the differentiation and proliferation of adipose-derived stem cells more effectively than either HA fraction alone. This may explain Profhilo's observed tissue-firming effect beyond simple hydration.

In a 3D skin model study, Stellavato et al. (2016) found that HCCs increased production of collagen types I, III, IV, and VII and elastin compared with untreated cells and with either HA fraction alone. This multi-collagen response is the biological basis for the visible improvement in skin firmness, elasticity, and texture reported in clinical studies.

The BAP injection technique

Profhilo is administered using the Bio Aesthetic Points (BAP) technique — five injection points on each side of the face, for a total of ten. The injection sites are chosen for anatomical safety and to allow the product to diffuse evenly across the mid and lower face:

1. At the zygomatic arch
2. On the tragus
3. At the nasolabial fold origin
4. On the chin
5. At the jawline angle

Each injection delivers approximately 0.2 mL of product into the subcutaneous tissue. The BAP technique is designed to minimize bruising and avoid major vessels and nerves while maximizing surface area coverage as the low-viscosity product spreads through tissue.

A standard initial protocol consists of two sessions spaced four weeks apart. The first session initiates fibroblast activation; the second consolidates the collagen and elastin response. Some practitioners add a third session for patients with more advanced skin laxity. Maintenance is typically recommended every six months.

Treatment time is approximately 15–20 minutes. Topical anesthetic is optional — most patients report the injections as tolerable, with brief stinging at each site.

What the clinical evidence shows

The evidence base for Profhilo has grown substantially since its launch. A 2025 systematic review published in BioMed Research International (PMCID: PMC13038071) analyzed nine studies involving 278 participants and found that Profhilo treatment led to:

• Statistically significant improvements in skin viscoelasticity, elasticity, and plastoelasticity parameters across the face, neck, arms, abdomen, and hands
• Significant improvements in skin hydration measured by electrical capacitance
• Improvements in skin density parameters
• Reductions in Wrinkle Severity Rating Scale (WSRS) and Facial Volume Loss Scale (FVLS) scores
• Improved skin turgor, tone, and texture on photographic documentation

A 2022 study published in Clinical, Cosmetic and Investigational Dermatology (PMCID: PMC9509274) evaluated Profhilo specifically for neck skin laxity in 25 subjects aged 40–65. Two injections at 30-day intervals produced statistically significant improvement in skin firmness and elasticity in all subjects, with concordant results between clinical, instrumental, and patient self-assessment.

A 2020 safety analysis published in BioMed Research International (PMCID: PMC7327616) reviewed worldwide postmarketing data and found that adverse events were mild and expected — primarily bruising, edema, and small injection-site bumps, typically resolving within 72 hours. No serious adverse events were reported.

For Profhilo Structura, a newer formulation with higher HA concentration (45 mg/mL) targeting the deep fat compartment, a pilot study published in Health Science Reports (PMCID: PMC10801275) demonstrated statistically significant improvement in facial volume loss and skin lifting in 50 subjects, with effects maintained at four months.

Regulatory status: not FDA-approved in the US

Profhilo does not currently have FDA approval in the United States. It holds CE marking in Europe and is widely available in the UK, EU, Latin America, Asia, and the Middle East. Patients in the US seeking a similar mechanism may encounter Skinvive (by Allergan), which is FDA-approved for improving skin smoothness of the cheeks. Skinvive uses microdroplets of cross-linked HA rather than Profhilo's non-cross-linked hybrid complexes, so the mechanism and biological effect are not identical.

The absence of FDA approval means Profhilo is not legally available in US clinics that operate under FDA device regulations. Patients should be cautious about any US clinic claiming to offer Profhilo.

Cost and what to expect

Pricing varies significantly by market and clinic:

• UK: £200–£450 per session; £500–£800 for a two-session course
• Europe: €300–€600 per session
• Markets where available: $350–$650 per session; $700–$1,200 for a two-session course

Results begin to appear approximately 2–4 weeks after the first session, with optimal results visible at 6–8 weeks after the second session. Effects typically last 6–12 months depending on individual skin quality, age, and lifestyle. Maintenance every 6 months is commonly recommended.

Who Profhilo is — and is not — for

Good candidates:

• Patients aged 30–60 with mild to moderate skin laxity
• Those seeking skin quality improvement without changing facial shape
• Patients with crepey or dehydrated skin on the face, neck, or hands
• Those wanting a biologically driven approach rather than a structural filler
• Patients who want minimal downtime

Not ideal for:

• Patients seeking significant volume restoration or contour reshaping (fillers or biostimulators like Sculptra are more appropriate)
• Those with active skin infections or inflammatory conditions at the injection sites
• Patients with severe skin laxity where surgical intervention may be more effective
• Patients in the United States, where Profhilo is not yet approved

Profhilo vs dermal fillers vs skin boosters

Profhilo does not compete with fillers — it addresses a different problem. Fillers replace lost volume. Profhilo improves the quality of the skin itself. Many treatment plans combine both.

Sources

• Stellavato A, La Noce M, Corsuto L, et al. Hybrid complexes of high and low molecular weight hyaluronans highly enhance HASCs differentiation: implication for facial bioremodelling. Cell Physiol Biochem. 2017;44:1078–1092. https://pubmed.ncbi.nlm.nih.gov/29179206

• Cassuto D, Delledonne M, Zaccaria G, et al. Safety assessment of high- and low-molecular-weight hyaluronans (Profhilo) as derived from worldwide postmarketing data. Biomed Res Int. 2020;2020:8159047. https://pmc.ncbi.nlm.nih.gov/articles/PMC7327616

• Sparavigna A, Tenconi B. Efficacy and tolerance of an injectable medical device containing stable hybrid cooperative complexes of high- and low-molecular-weight hyaluronic acid: a monocentric 16-week evaluation. Clin Cosmet Investig Dermatol. 2016;9:297–305. https://pmc.ncbi.nlm.nih.gov/articles/PMC5044990

• Systematic review of the efficacy and safety of Profhilo and Profhilo Body. BioMed Research International. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC13038071

• Sparavigna A, et al. Efficacy and tolerability of hybrid complexes of high- and low-molecular-weight hyaluronan intradermal injections for treatment of skin roughness and laxity of the neck. Clin Cosmet Investig Dermatol. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9509274

• Sparavigna A, et al. Efficacy and tolerability of Profhilo Structura intended to restore lateral cheek fat compartment: an observational pilot study. Health Sci Rep. 2024;7:e1743. https://pmc.ncbi.nlm.nih.gov/articles/PMC10801275